Biotech Startups

DNAstack builds Omics AI, a software suite that lets data custodians connect, protect, and share omics and health data across federated networks while enabling researchers to discover, access, and analyze it with AI tools. It serves genomics and health research organizations, including national and international research networks in areas such as pandemic surveillance, neuroscience, rare disease, and oncology, using open GA4GH standards.

1 investor

Dr. Evidence operates a pharma labeling and regulatory intelligence platform that aggregates content such as drug labels, regulatory packages, and clinical trials and applies proprietary AI models to support life sciences clients in bringing products to market and maintaining regulatory compliance. It offers workflows and automated monitoring for tasks like tracking label changes, preparing submissions, and analyzing competitive precedent.

1 investor

Docufen lets life-science and pharmaceutical teams fill in their existing GxP Word documents—such as batch records, validation forms, and logbooks—with traceable, compliant digital data entries including signatures, text, and attachments. It is a compliance-focused documentation tool aimed at regulated manufacturing environments.

1 investor

Dolby Ventures is an investment firm focused on life sciences, investing across precision neuroscience (neurodegeneration, psychiatry, and neurotech via therapeutics, devices, and diagnostics) and life sciences platforms such as de novo platforms, regenerative medicine, and computational biology. It applies a polymedicine approach to treat complex diseases and does not invest in non-platform companies in oncology, cardiovascular, or rare diseases.

1 investor

Dolinnov is a pharmaceutical company developing next-generation painkillers based on a Precision Pump Modulator that targets the ion pump driving neuronal hyperexcitability rather than blocking ion channels. It focuses on treatments for extreme chronic pain and other serious diseases with significant unmet medical needs.

1 investor

Domainex is a contract research organisation providing integrated drug discovery services, including medicinal chemistry, biosciences, structural biology, and DMPK, to pharmaceutical and biotech clients. It offers specialised capabilities such as membrane protein production, assay development, compound screening, and computer-aided drug design.

1 investor

Dutscher provides after-sales service (SAV) and post-delivery support (SAL) for laboratory equipment and consumables, handling warranty claims, non-warranty repairs, maintenance, product returns, and transport damage resolution.

1 investor

Domus develops molecular testing platforms that perform nucleic acid detection in a single-step reaction across three deployment models: at-home rapid tests, clinic-based instruments, and central laboratory assays. The company serves clinical diagnostics and at-home testing markets with technology optimized for sensitivity, simplicity, and low cost.

1 investor

Dotmatics develops Luma, an agentic AI platform for scientific research that analyzes data, generates audit-ready reports, configures data models and workflows, and connects to existing lab systems. It serves scientists and R&D teams, keeping data structured, governed, and traceable across the research stack.

1 investor

Publicly listed pharmaceutical company

1 investor

The Medical University of Graz is a public medical university in southern Austria where staff and students conduct research, teaching, and learning focused on patient health and well-being. It also contributes to patient care at its location.

1 investor

The Medical University of Vienna (Medizinische Universität Wien) is a public academic and research institution focused on medicine and the health sciences. It provides medical education, research, and clinical activities in Austria.

1 investor

Dragonfly develops immunotherapy treatments that leverage the body's immune system to treat cancer and autoimmune diseases. The company's therapies are designed to function as standalone agents or in combination with existing disease-targeting treatments.

1 investor

DR.C Medicine (DRC Medicine Ltd.) is a Japanese company specializing in allergy and infectious-disease countermeasures, developing and selling pharmaceuticals, medical devices, quasi-drugs, healthcare and cosmetic products. It develops materials based on its Hydro Silver Titanium technology, used in products such as masks, towels, socks and air purifiers.

1 investor

Muu develops animal-free proteins using precision fermentation, cultivating proprietary microbial hosts to bio-manufacture protein that is then purified into a high-purity protein powder. Its ingredients target the nutrition and fitness supplement market with a lower land, water, and greenhouse-gas footprint than animal-derived protein.

1 investor

Drishti Discoveries develops RNA-targeting genetic therapies for neurodegenerative diseases, combining RNAi therapeutics with gene therapy via a patented artificial microRNA technology. Its approach aims for sustained knockdown of target gene expression to deliver long-term therapeutic effects.

1 investor

Droia Ventures is a specialist venture capital firm investing globally in early-stage drug development companies focused on therapeutics for oncology and genetic disease. It backs and co-creates biotech companies, supporting them from formation through clinical proof of concept via its in-house team and its scientific arm, Droia Labs.

1 investor

DropCode uses proprietary droplet microfluidics with a dual barcode technology to run millions of protein-screening experiments per hour, combined with AI analysis to discover novel, optimized proteins for customers. The company applies high-throughput biological data-mining to characterize protein function and design new-to-nature proteins.

1 investor

DropLab is a multidisciplinary engineering firm specializing in microfluidics technology, serving customers with challenges in nanotechnology, biomedicine, and materials engineering.

1 investor

Dropprint Genomics develops software for analyzing individual cell activity in genomic data, serving researchers in immunology and drug discovery. The company reduces the cost and computational complexity of single-cell sequencing and maintains a database of over 1 million immune cells to support target identification using machine learning models.

1 investor

DrugBank develops a comprehensive drug knowledge base and API that provides curated, machine-learning ready data on drugs and drug products to pharmaceutical companies, researchers, and healthcare organizations. The company makes scientific findings and biomedical information accessible to improve medical outcomes and drug discovery.

1 investor

The Dry Lab builds tools that help researchers and organizations convert raw data into discoveries through connected systems and intelligent automation.

1 investor

Dryland Genetics is a plant breeding company developing productive, resilient crop varieties, with expertise in the North American corn market and broader crop genetics. It applies crop biology, genetics, and bioinformatics to build commercial seed portfolios.

1 investor

Drylet develops bioremediation products, including ManureMagic and Bio Dredger, along with sonar mapping services to treat wastewater and organic waste, reduce sludge, and improve treatment system performance. It serves municipal, industrial, and agricultural wastewater operators and lagoons.

1 investor